(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Vote In favor of Your Favored Treat - 2Figure out How to Recognize the Right Areas for 5G Pinnacles\
- 3Fossil analysis changes what paleontologists know about how long T. rex took to grow full size
- 4Vacuum Cleaners That Are Not difficult To Use For Home
- 5Figure out How to Protect Your Gold Venture from Unpredictability
- Top 15 Supportable Design Brands Coming out on top
- European nations criticise Israel’s death penalty plans
- Top 15 Style Creators Changing the Business
- Disney's latest short film 'Versa' tackles a difficult subject: Pregnancy loss. It's resonating with viewers.
- Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- 3 moms, 3 countries, 1 very familiar problem: Why child care costs still don't add up for families
- Eight arrested in joint Scotland and Spain gang raids
- Find the Native Culinary Customs: Local Flavors
- No more attempts to free whale stranded off Germany, officials say
